Furthermore, LY3484356 has displayed additivity in combination with CDK4/6 inhibitors, mTOR inhibitors, and PIK3CA inhibitors in blocking cell proliferation, as well as tumor growth inhibition in xenograft and PDX models of breast cancer. This evidence concerns the gene PIK3CA and neoplasm.